Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) EBITDA (2019 - 2025)

Biodesix's EBITDA history spans 7 years, with the latest figure at -$2.0 million for Q4 2025.

  • For Q4 2025, EBITDA rose 70.42% year-over-year to -$2.0 million; the TTM value through Dec 2025 reached -$27.9 million, up 19.2%, while the annual FY2025 figure was -$27.9 million, 19.2% up from the prior year.
  • EBITDA reached -$2.0 million in Q4 2025 per BDSX's latest filing, up from -$7.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$2.0 million in Q4 2025 to a low of -$16.4 million in Q1 2023.
  • Average EBITDA over 5 years is -$9.8 million, with a median of -$10.2 million recorded in 2021.
  • Peak YoY movement for EBITDA: tumbled 340.22% in 2021, then skyrocketed 70.42% in 2025.
  • A 5-year view of EBITDA shows it stood at -$11.7 million in 2021, then fell by 18.93% to -$13.9 million in 2022, then skyrocketed by 50.54% to -$6.9 million in 2023, then increased by 3.22% to -$6.6 million in 2024, then surged by 70.42% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for BDSX's EBITDA are -$2.0 million (Q4 2025), -$7.1 million (Q3 2025), and -$9.7 million (Q2 2025).